Antibody persistence against diphtheria, tetanus, pertussis, hepatitis B, measles, mumps and rubella in 9-12-year-old Thai children following immunization with pentavalent and hexavalent vaccines, and the immunogenicity of Tdap administered at 11 years of age
- Conditions
- Children aged 9-12 years who are healthy with previous immunization with either pentavalent or hexavalent vaccines. Informed consent obtained from parents/guardians.diphtheriatetanuspertussishepatitis Bmeaslesmumpsrubella
- Registration Number
- TCTR20240723005
- Lead Sponsor
- Ratchadapiseksomphot Endowment Fund, Chulalongkorn University
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Pending (Not yet recruiting)
- Sex
- All
- Target Recruitment
- 250
Children aged 9-12 years
Previous immunization with either pentavalent or hexavalent vaccines
Informed consent obtained from parents/guardians
1. Serious underlying medical condition e.g. genetic disorder such as Down syndrome, children in immunosuppressive state or receiving immunosuppressive agents, human immunodeficiency virus infection, chronic lung or heart disease, chronic liver or kidney disease, history of chronic or recurrent infections.
2. Primary or secondary humoral immune disorders
3. History of adverse reactions to vaccines
4. Participation in another clinical study
Study & Design
- Study Type
- Observational
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method antibody levels to hepatitis B annually ELISA
- Secondary Outcome Measures
Name Time Method antibody levels to DTP Annually ELISA,antibody levels to MMR Annually ELISA
Related Research Topics
Explore scientific publications, clinical data analysis, treatment approaches, and expert-compiled information related to the mechanisms and outcomes of this trial. Click any topic for comprehensive research insights.